After 3 months of taking oral semaglutide, 32 people with type 2 diabetes saw a better balance between muscle mass and belly fat, which improved further by 6 months but wasn't statistically significant.
Scientific Claim
In 32 adults with type 2 diabetes, oral semaglutide use over 26 weeks was associated with a significant increase in skeletal muscle mass to visceral adipose tissue ratio at 3 months (from 8.2 to 9.3 kg/L), but not at 6 months.
Original Statement
“This resulted in a beneficial effect on the SMM/VAT ratio, a well-known index inversely related to CVR and sarcopenic visceral obesity. In fact, this ratio increased significantly at T3 compared with T0, and remained higher than at baseline at T6, although the latter change was no longer statistically significant.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study is observational with no control group, so causation cannot be established. The use of 'associated with' correctly reflects the evidence.